Mohsen Kerkeni1, Izabella Santos Weiss2, Stephane Jaisson2, Azza Dandana3, Faouzi Addad4, Philippe Gillery2, Mohamed Hammami5. 1. Laboratory of Biochemistry, LR12ES05, Faculty of Medicine, University of Monastir, Tunisia. Electronic address: mohsen.kerkeni@yahoo.fr. 2. Laboratory of Paediatric Biology and Research, American Memorial Hospital, University Hospital of Reims, Faculty of Medicine, Reims, France; Laboratory of Biochemistry and Molecular Biology, UMR CNRS/URCA n°7369, Faculty of Medicine, Reims, France. 3. Laboratory of Biochemistry, CHU-Farhat Hached, Sousse, Tunisia. 4. Department of Cardiology-University Hopital A. Mami, Ariana, Tunisia. 5. Laboratory of Biochemistry, LR12ES05, Faculty of Medicine, University of Monastir, Tunisia.
Abstract
BACKGROUND: There are limited data regarding the contribution of advanced glycation end products (AGEs) in the presence of coronary artery disease (CAD). We investigated whether serum pentosidine and Nε-carboxymethyllysine (CML) were related to the presence and the severity of CAD. METHODS: 69 Tunisian patients with CAD (≥ 50% obstruction in ≥ 1 coronary artery), 32 Tunisian patients without CAD but with potential cardiovascular risk factors and 60 Tunisian control subjects were included in a cross-sectional study. Patients were classified as CAD and non CAD patients according to angiographic results. The severity of CAD was assessed using the Gensini score. Serum pentosidine and CML were measured by LC-MS/MS. RESULTS: Serum pentosidine and CML concentrations were significantly higher in non-CAD patients vs control subjects (P<0.001). Serum pentosidine concentrations were significantly higher in CAD patients vs non-CAD patients (P<0.001). A multiple logistic regression analysis demonstrated that pentosidine was independently associated with the presence of CAD (OR=1.52, 95% CI: 1.12-2.07, P=0.007). The area under curve (AUC) determined by ROC analysis was 0.74 (95% CI: 0.64-0.84, P<0.001) and the optimal cut-off value of pentosidine to predict the presence of CAD was 3.2 μmol/mol Lys, with 64% sensitivity and 78% specificity. Furthermore, in a multivariate stepwise regression analysis, pentosidine was independently correlated with Gensini score (standardized β= 0.46, 95% CI: 0.70-1.99, P<0.001). CONCLUSIONS: High concentrations of pentosidine show the presence and the severity of CAD with high sensitivity.
BACKGROUND: There are limited data regarding the contribution of advanced glycation end products (AGEs) in the presence of coronary artery disease (CAD). We investigated whether serum pentosidine and Nε-carboxymethyllysine (CML) were related to the presence and the severity of CAD. METHODS: 69 Tunisian patients with CAD (≥ 50% obstruction in ≥ 1 coronary artery), 32 Tunisian patients without CAD but with potential cardiovascular risk factors and 60 Tunisian control subjects were included in a cross-sectional study. Patients were classified as CAD and non CAD patients according to angiographic results. The severity of CAD was assessed using the Gensini score. Serum pentosidine and CML were measured by LC-MS/MS. RESULTS: Serum pentosidine and CML concentrations were significantly higher in non-CAD patients vs control subjects (P<0.001). Serum pentosidine concentrations were significantly higher in CAD patients vs non-CAD patients (P<0.001). A multiple logistic regression analysis demonstrated that pentosidine was independently associated with the presence of CAD (OR=1.52, 95% CI: 1.12-2.07, P=0.007). The area under curve (AUC) determined by ROC analysis was 0.74 (95% CI: 0.64-0.84, P<0.001) and the optimal cut-off value of pentosidine to predict the presence of CAD was 3.2 μmol/mol Lys, with 64% sensitivity and 78% specificity. Furthermore, in a multivariate stepwise regression analysis, pentosidine was independently correlated with Gensini score (standardized β= 0.46, 95% CI: 0.70-1.99, P<0.001). CONCLUSIONS: High concentrations of pentosidine show the presence and the severity of CAD with high sensitivity.
Authors: Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier Journal: J Am Soc Nephrol Date: 2015-08-26 Impact factor: 10.121
Authors: Katherine L O'Grady; Sundeep Khosla; Joshua N Farr; Olga P Bondar; Elizabeth J Atkinson; Sara J Achenbach; Brittany A Eckhardt; Brianne S Thicke; Amanda J Tweed; Tammie L Volkman; Matthew T Drake; Jolaine M Hines; Ravinder J Singh Journal: J Appl Lab Med Date: 2020-05-01
Authors: Yuliya V Markina; Elena V Gerasimova; Alexander M Markin; Victor Y Glanz; Wei-Kai Wu; Igor A Sobenin; Alexander N Orekhov Journal: Int J Mol Sci Date: 2020-07-31 Impact factor: 5.923
Authors: Craig Basman; Sarah L Fishman; Dimiter Avtanski; Umar Rashid; Arber Kodra; Karin Chen; Rebecca Jonas; Guillaume J Stoffels; Martin Lesser; Damian Inlall; Karina Ziskovich; Varinder Singh; Leonid Poretsky Journal: Metabol Open Date: 2020-08-16